Surgery

Five years after the COVID-19 pandemic shutdown reshaped how the world gathers, here's how some of ophthalmology’s leading associations are still applying lessons forged in crisis

Personalizing treatment options and setting realistic expectations are crucial.

The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss.

Vision correction has evolved into a continuum of procedures suited for different stages of ocular maturity

A combination of canaloplasty and goniotomy provides sustained IOP reduction and decreases medication burden with a strong safety profile, making it a valuable option for glaucoma management.

The recent agreement with Cipla adds to the list of partnerships Formosa has formed for APP13007.

These offerings are designed to streamline workflows for eye care professionals and enhance patient experience.

This preservative-free synthetic corticosteroid is approved by the FDA for visualization during vitrectomy and the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids.

The research analyzed the 1-year outcomes of 132 eyes, evaluating mean IOP, baseline changes, medication reduction, and stratifying the results by race (African American vs Caucasian) and glaucoma severity (mild, moderate, severe).

The procedure offers a renewed approach to suprachoroidal drainage, with potential for both combined and standalone glaucoma surgery.

The Elios procedure increased aqueous humor outflow in all investigated eyes, but further studies are needed to correlate these improvements with its clinical efficacy.

Monofocal IOLs, along with advanced phacoemulsification technology, offer tailored solutions.

Shameema Sikder, MD; and T. Y. Alvin Liu, MD, highlight the technology’s role in bridging challenges and successes for clinical practice.

The state-of-the-art facility more than doubles the institute’s footprint, enhancing patient care, research, and education.

Direct selective laser trabeculoplasty enhances the experience for both patients and physicians, he notes, while also mitigating issues related to poor adherence and ocular surface disease from topical therapy.

The new first-line laser treatment for glaucoma and ocular hypertension will be unveiled at the 2025 American Glaucoma Society annual meeting in Washington, DC, from February 26 to March 2.

The focus in recent years has shifted to reducing the long-term burden of medical therapy, minimizing the risk of medication toxicity and persistent ocular surface disease.

The company plans on launching VIA360 immediately in the US market.

Ooms' poster at the Association of University Professors of Ophthalmology annual meeting highlighted a study on gray area complications in strabismus surgery, showing that trainees are more likely than attendings to disclose these complications despite having similar baseline anxiety levels. Ooms is a PGY-4 ophthalmology resident at the Dean McGee Eye Institute.

The pandemic caused an overall decrease in the rates of the 10 most common ophthalmic procedures performed in 2020 when compared to the year prior.

Sonia H. Yoo, MD, a cornea, cataract, and refractive surgery specialist and a member of the planning committee for the EnVision Summit, highlights a session focused on the latest advancements in lens implant technologies, refractive procedures, and imaging innovations. The summit will be held from February 14 to 17, 2025, at the Caribe Hilton San Juan in Puerto Rico.

Real-world scenarios showcase a shift in treatment paradigms

From easing fears to improving mood, a recent study explores how music transforms the surgical experience for both patients and health care teams.

Through its ophthalmic program, Mercy Ships provides critical eye surgeries and trains local professionals, ensuring sustainable eye care for the future.

As Ophthalmology Times celebrates 50 years of publication and the Wilmer Eye Institute marks 100 years of academic leadership, Peter J. McDonnell, MD, reflects on their shared commitment to helping ophthalmologists improve patient outcomes.

Funds from the Inasmuch Foundation and The Samuel Roberts Noble Foundation will support the purchase of equipment, including computerized eye simulators, a laser injector, and a device for measuring the electrical resistance of cells.

Dr. Frenkel highlights a comprehensive program that covers the latest breakthroughs in glaucoma and cataract surgery to in-depth discussions on AI, retinal treatments, and new drug-delivery platforms, all set against the backdrop of Snowmass, Colorado.

Wendy Lee, MD, an oculoplastics specialist and member of the program committee at EnVision Summit, shares an agenda that will include a mix of functional oculoplastics, aesthetics, and live facial rejuvenation demonstrations at the upcoming event, which will be held from February 14 to 17, 2025, at the Caribe Hilton San Juan in Puerto Rico.

Glaucoma specialists discuss pairing patients with the right procedures.

A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect anatomical or functional outcomes after epiretinal membrane surgery.